Stocktoria
PRECISION BIOSCIENCES INC DTIL
PRECISION BIOSCIENCES INC (DTIL) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $34.3M at a -133.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.711 |
| Retained earnings / assets | -3.421 |
| EBIT / assets | -0.338 |
| Equity / liabilities | 1.484 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| DTIL | PRECISION BIOSCIENCES INC | 1/9 | -7.2 | — | -50.1% |
| XFOR | X4 Pharmaceuticals, Inc | 3/9 | -1.48 | — | — |
| CCCC | C4 Therapeutics, Inc. | 3/9 | -2.12 | — | +1% |
| SCLX | Scilex Holding Co | 2/9 | — | — | -46.5% |
| KYMR | Kymera Therapeutics, Inc. | 3/9 | 9.79 | — | -16.7% |
| SGMO | SANGAMO THERAPEUTICS, INC | 2/9 | — | — | -31.6% |
| VYGR | Voyager Therapeutics, Inc. | 1/9 | -1.03 | — | -49.5% |
About PRECISION BIOSCIENCES INC
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
FAQ
Is DTIL financially healthy?
PRECISION BIOSCIENCES INC's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does DTIL pay a dividend?
No, PRECISION BIOSCIENCES INC does not currently pay a dividend.
How profitable is DTIL?
In FY2025, PRECISION BIOSCIENCES INC had a net margin of -133.4% and a return on equity of -49.6%.
What is the analyst price target for DTIL?
The average Wall-Street price target for PRECISION BIOSCIENCES INC is $29.60, about 298.9% above the recent price, from 5 analysts.
Is DTIL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on PRECISION BIOSCIENCES INC: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.